Study: Pfizer COVID-19 vaccine provides 94% protection

On Thursday, the results of a new study confirmed that the Pfizer COVID-19 vaccine can provide 94% protection, CBS reported.

The study observed more than half a million persons who were vaccinated by the two-shot vaccine, in addition, the vaccine proved its capability of preventing serious illness or death by the virus.

Conducted by Clalit Research Institue in cooperation with Harvard University, the study was applied on 600,000 persons who were vaccinated by the vaccine and their ages are over 16 years old.

Moreover, the study observed the interaction between two groups of people: vaccinated group, and non-vaccinated group, and it was confirmed that the one shot of the vaccine is 57% effective in protecting against COVID-19 infection, on the other hand, the vaccine also proved to be 62% effective at preventing severe disease after one shot, and 92% effective after two.

The total contributed persons in the study was 1.2 million persons.

Last week, medical firms Pfizer and BioNTech published a new study showing the impact of the vaccine after storing it at normal freezer temperatures for two weeks.

The study asserted that the Pfizer vaccine remains effective after storing in normal freezers for two weeks.

The initial data about the Pfizer vaccine showed that it should be restored at -70°C which requires expensive and specialized freezers to keep the vaccine doses.

Therefore, the firm developed a shopping box cooled by dry ice that could keep the required temperatures for the vaccine doses.

However, the new study that showed the possibility of storing the vaccine between –15°C and –25°C can make the distribution of the vaccine doses somehow easier.

Moreover, the first dose of the COVID-19 vaccine showed 92.6% efficacy compared with 95% efficacy after both doses.